Cargando…

Neoadjuvant immunotherapy combined with chemotherapy for local advanced non-small cell lung cancer: a case report

Immunotherapy has revolutionized lung cancer management and revitalized the field of tumor immunology. Anti-programmed death 1 (anti-PD-1) immunotherapy can significantly improve the survival of patients with advanced non-small cell lung cancer (NSCLC), but its role in neoadjuvant therapy of local a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Jie, Xia, Haoran, Sun, Fenghuan, Zhang, Peng, Jiang, Gening
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106098/ https://www.ncbi.nlm.nih.gov/pubmed/33987422 http://dx.doi.org/10.21037/atm-21-1565

Ejemplares similares

Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing
por: Hu, Junjie, et al.
Publicado: (2023)

Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study
por: Bian, Dongliang, et al.
Publicado: (2023)

Neoadjuvant Immunotherapy Combined with Chemotherapy for Local Advanced Non-Small-Cell Lung Cancer in a Patient with a History of Breast Cancer: A Case Report
por: Yang, Rui-Xia, et al.
Publicado: (2022)

Neoadjuvant therapy for locally advanced non-small cell lung cancer: TKIs or immunotherapy?
por: Zhang, Zhenyang, et al.
Publicado: (2020)

Sleeve resection after neoadjuvant chemoimmunotherapy in the treatment of locally advanced non-small cell lung cancer
por: Dai, Jie, et al.
Publicado: (2022)

A case study of combined neoadjuvant chemotherapy and neoadjuvant immunotherapy in resectable locally advanced esophageal cancer
por: Dai, Huiru, et al.
Publicado: (2022)

Neoadjuvant Chemo-Immunotherapy for Locally Advanced Non-Small-Cell Lung Cancer: A Review of the Literature
por: Franzi, Sara, et al.
Publicado: (2022)

Neoadjuvant immunotherapy combined with chemotherapy for locally advanced squamous cell lung carcinoma: A case report and literature review
por: Zheng, Yuan, et al.
Publicado: (2021)

Neoadjuvant Nivolumab and Chemotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer: A Retrospective Study
por: Zhai, Hengyu, et al.
Publicado: (2022)

Neoadjuvant sintilimab combined with chemotherapy in resectable locally advanced non-small cell lung cancer: case series and literature review
por: Yin, Cunli, et al.
Publicado: (2023)

Sleeve lobectomy after neoadjuvant chemoimmunotherapy/chemotherapy for local advanced non-small cell lung cancer
por: Liang, Hengrui, et al.
Publicado: (2021)

Neoadjuvant immunotherapy combined with chemotherapy significantly improved patients’ overall survival when compared with neoadjuvant chemotherapy in non-small cell lung cancer: A cohort study
por: Dai, Fuqiang, et al.
Publicado: (2022)

Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in locally advanced esophageal cancer: A meta-analysis
por: Wang, Jincheng, et al.
Publicado: (2022)

Real-world multicentre analysis of neoadjuvant immunotherapy and chemotherapy in localized or oligometastatic non-small cell lung cancer (KOMPASSneoOP)
por: Faehling, Martin, et al.
Publicado: (2022)

Efficacy and safety of camrelizumab (a PD-1 inhibitor) combined with chemotherapy as a neoadjuvant regimen in patients with locally advanced non-small cell lung cancer
por: Hou, Xinlei, et al.
Publicado: (2022)

Advances in efficacy prediction and monitoring of neoadjuvant immunotherapy for non-small cell lung cancer
por: Wang, Yunzhen, et al.
Publicado: (2023)

Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma
por: Wu, Zhigang, et al.
Publicado: (2021)

The prospect of immunotherapy combined with chemotherapy in patients with advanced non-small cell lung cancer: a narrative review
por: Ning, Xiangu, et al.
Publicado: (2021)

Neoadjuvant immunotherapy in resectable non-small-cell lung cancer
por: Chen, Lanyi Nora, et al.
Publicado: (2023)

Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer
por: Wang, Xue, et al.
Publicado: (2021)

Neoadjuvant immunotherapy and neoadjuvant chemotherapy in resectable non-small cell lung cancer: A systematic review and single-arm meta-analysis
por: Wang, He, et al.
Publicado: (2022)

Neoadjuvant immunotherapy with resectable non-small cell lung cancer: recent advances and future challenges
por: Ren, Sijia, et al.
Publicado: (2020)

Efficacy and safety evaluation of neoadjuvant immunotherapy plus chemotherapy for resectable non–small cell lung cancer in real world
por: Fang, Min, et al.
Publicado: (2023)

Safety and effectiveness of localized lung resection combined with neoadjuvant chemotherapy in the treatment of stage I–II non-small cell lung cancer
por: Zhu, Bing, et al.
Publicado: (2017)

Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II–III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial
por: Zhu, Xinsheng, et al.
Publicado: (2022)

Comprehensive study of neoadjuvant targeted therapy for resectable non-small cell lung cancer
por: Bao, Yi, et al.
Publicado: (2021)

Neoadjuvant chemotherapy in combination with surgery in the treatment of local advanced breast cancer
por: Zhao, Haixia, et al.
Publicado: (2019)

The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer
por: Jiang, Long, et al.
Publicado: (2021)

Neoadjuvant PD-1 blockade combined with chemotherapy is not superior to neoadjuvant chemotherapy alone in resectable locally advanced esophageal carcinoma
por: Cheng, Daoan, et al.
Publicado: (2023)

A pathological complete response to neoadjuvant chemotherapy and immunotherapy in a non-small cell lung cancer patient
por: Gao, Pengqiang, et al.
Publicado: (2020)

Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer
por: Qiu, Bin, et al.
Publicado: (2021)

Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer
por: Liang, Wenhua, et al.
Publicado: (2020)

Real-World Effectiveness and Prognostic Factors Analysis of Stages I–III Non-Small Cell Lung Cancer Following Neoadjuvant Chemo-Immunotherapy or Neoadjuvant Chemotherapy
por: Liu, Zuo, et al.
Publicado: (2021)

Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients
por: Xiong, Liwen, et al.
Publicado: (2019)

Neoadjuvant immunotherapy for non–small cell lung cancer: State of the art
por: Kang, Jin, et al.
Publicado: (2021)

Clinical challenges in neoadjuvant immunotherapy for non-small cell lung cancer
por: Guo, Hanfei, et al.
Publicado: (2021)

Neoadjuvant chemotherapy for locally advanced cervical cancer
por: Iwata, Takashi, et al.
Publicado: (2016)

Neoadjuvant chemotherapy in locally advanced duodenal adenocarcinoma
por: Velandia, Carlos, et al.
Publicado: (2018)

Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer
por: Papaccio, Federica, et al.
Publicado: (2020)

The power of immunotherapy plus platinum–based chemotherapy for locally advanced or early stage non-small cell lung cancer
por: Hofman, Paul
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_15h2akpb6scn1j4d3uc3rmrmkv